Time to and Time in Better Health States With Sotatercept for Pulmonary Arterial Hypertension: A Modeling Study
Author(s)
ARISTEIDIS DRAGANIGOS, MSc1, ANASTASIOS SKROUMPELOS, PhD1, Rogier Klok, PharmD, PhD2, Urs Arnet, PhD3, Johannes Michel, PhD4, Murvin Jootun, MSc5.
1MSD Greece, Athens, Greece, 2MSD, Twello, Netherlands, 3MSD, Zürich-Airport, Switzerland, 4MSD International, Schlierbach, Switzerland, 5MSD, London, United Kingdom.
1MSD Greece, Athens, Greece, 2MSD, Twello, Netherlands, 3MSD, Zürich-Airport, Switzerland, 4MSD International, Schlierbach, Switzerland, 5MSD, London, United Kingdom.
OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic, progressive disease that significantly reduces patients’ quality of life (QoL) and imposes a substantial burden on families and healthcare systems. In managing PAH, maintaining patients in better health states for longer periods is critical. Prolonged better health outcomes not only delay disease progression and associated costs but also reduce caregiver burden and support long-term well-being.
METHODS: A previously published Markov model was used to simulate disease progression with sotatercept versus background therapy (BGT) in Greece, across high-, intermediate-high (IH), and intermediate-low (IL) risk status. Patients were classified into these risk groups at the start of the analysis. Key outcomes included time spent in better or not worse health states and time to better health states. Model inputs were informed by the STELLAR trial and peer-reviewed literature on risk status transitions and survival.
RESULTS: In high-risk patients, time in better health states was 12.21 years with sotatercept versus 1.85 years with BGT; time in not worse health states was 13.98 years versus 3.84 years. For IH-risk patients, these durations were 15.65 and 16.21 years with sotatercept, compared to 1.40 and 2.29 years with BGT. IL-risk patients experienced 12.85 and 15.50 years in better and not worse health states with sotatercept, versus 1.44 and 2.75 years with BGT. Median time to improvement was 3 weeks for high-risk patients in both arms, 12 weeks for IH-risk patients with sotatercept versus 84 weeks with BGT, and 12 weeks for IL-risk patients with sotatercept versus over 180 weeks with BGT.
CONCLUSIONS: Sotatercept offers substantial long-term value in PAH by significantly increasing the time patients live in better or not worse health states. This sustained benefit supports improved QoL, reduced caregiver burden, and defers worse health state management cost into the future, reinforcing sotatercept’s value for patients, families and the healthcare system.
METHODS: A previously published Markov model was used to simulate disease progression with sotatercept versus background therapy (BGT) in Greece, across high-, intermediate-high (IH), and intermediate-low (IL) risk status. Patients were classified into these risk groups at the start of the analysis. Key outcomes included time spent in better or not worse health states and time to better health states. Model inputs were informed by the STELLAR trial and peer-reviewed literature on risk status transitions and survival.
RESULTS: In high-risk patients, time in better health states was 12.21 years with sotatercept versus 1.85 years with BGT; time in not worse health states was 13.98 years versus 3.84 years. For IH-risk patients, these durations were 15.65 and 16.21 years with sotatercept, compared to 1.40 and 2.29 years with BGT. IL-risk patients experienced 12.85 and 15.50 years in better and not worse health states with sotatercept, versus 1.44 and 2.75 years with BGT. Median time to improvement was 3 weeks for high-risk patients in both arms, 12 weeks for IH-risk patients with sotatercept versus 84 weeks with BGT, and 12 weeks for IL-risk patients with sotatercept versus over 180 weeks with BGT.
CONCLUSIONS: Sotatercept offers substantial long-term value in PAH by significantly increasing the time patients live in better or not worse health states. This sustained benefit supports improved QoL, reduced caregiver burden, and defers worse health state management cost into the future, reinforcing sotatercept’s value for patients, families and the healthcare system.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO251
Topic
Clinical Outcomes, Economic Evaluation, Health Technology Assessment
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)